- English (USA)
- English (UK)
- English (India)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Xeris Biopharma Holdings, Inc (XERS)
Xeris Biopharma Holdings, Inc stock price live, this page displays NASDAQ XERS stock exchange data. View the XERS premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Xeris Biopharma Holdings, Inc real time stock price chart below.
What Is the Xeris Biopharma Holdings, Inc Stock Price Today?
The Xeris Biopharma Holdings, Inc stock price today is 9.970.
What Is the Stock Symbol for Xeris Biopharma Holdings, Inc?
The stock symbol for Xeris Biopharma Holdings, Inc is "XERS."
What Stock Exchange Does Xeris Biopharma Holdings, Inc Trade On?
Xeris Biopharma Holdings, Inc is listed and trades on the NASDAQ stock exchange.
Is Xeris Biopharma Holdings, Inc a Good Stock to Buy?
Determining whether Xeris Biopharma Holdings, Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the XERS quote. (ISIN: US98422E1038)
What Is the Xeris Biopharma Holdings, Inc Stock Price Today?
The Xeris Biopharma Holdings, Inc stock price today is 9.970.
What Is the Stock Symbol for Xeris Biopharma Holdings, Inc?
The stock symbol for Xeris Biopharma Holdings, Inc is "XERS."
What Stock Exchange Does Xeris Biopharma Holdings, Inc Trade On?
Xeris Biopharma Holdings, Inc is listed and trades on the NASDAQ stock exchange.
Is Xeris Biopharma Holdings, Inc a Good Stock to Buy?
Determining whether Xeris Biopharma Holdings, Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the XERS quote. (ISIN: US98422E1038)
9.970
+0.200(+2.05%)
Real-time Data·
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
9.770
10.090
52 wk Range
5.250
11.330
XERS is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
9.77010.090
52 wk Range
5.25011.330
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
XERS Scorecard
Company’s Health
Assesses a company's financial position by analyzing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Buy
Analysts Sentiment
Strong Buy
Price Target
12.857
Upside
+28.96%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Net income is expected to drop this year
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Sell
Technical Indicators
Strong Sell
Moving Averages
Neutral
Analyst Ratings
6 Buy
1 Hold
0 Sell
Ratings:
7 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 12.857
(+28.96% Upside)
Xeris Biopharma Holdings, Inc Earnings Call Summary for Q1/2026
- Q1 2026 revenue rose 38% YoY to $83.1M; EPS of $0.01 beat forecasts despite minor revenue miss; stock climbed 4.55% to $6.66 in pre-market.
- RECORLEV revenue nearly doubled with 95% growth; company raised FY2026 guidance to $380-$390M, projecting 30%+ growth and $1B by 2035.
- Adjusted EBITDA improved $10.7M to $15.1M; net income turned positive at $2.2M vs. prior year loss; gross margin expanded to 87%.
- Gvoke faces Medicare policy headwinds; management pursuing pricing optimization and expanded patient access to offset demand challenges.
- CEO Edick emphasized strong commercial execution; CFO Shannon committed to sustained adjusted EBITDA growth through disciplined financial management.
Last Updated: 2026-05-07, 10:14 a/m
Read Full TranscriptEarnings
Latest Release
Aug 06, 2026
EPS / Forecast
-0.18 / 0.01
Revenue / Forecast
92.1M / 90.29M
Compare XERS to Peers and Sector
Metrics to compare | XERS | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipXERSPeersSector | |
|---|---|---|---|---|
P/E Ratio | −103.8x | 10.9x | −0.3x | |
PEG Ratio | −2.02 | 0.11 | 0.00 | |
Price/Book | −183.0x | 3.6x | 2.6x | |
Price / LTM Sales | 5.3x | 3.4x | 2.9x | |
Upside (Analyst Target) | 31.6% | 34.3% | 64.3% | |
Fair Value Upside | Unlock | 25.3% | 10.0% | Unlock |
Xeris Biopharma Holdings, Inc., a commercial-stage biopharmaceutical company, engages in developing and commercializing therapies for chronic endocrine and neurological diseases in Illinois. It offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia in pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor for the treatment of endogenous hypercortisolemia in adult patients with Cushing’s syndrome. It is also developing XP-8121, a once-weekly subcutaneous injection of levothyroxine that is in phase 3 clinical trial for the treatment of hypothyroidism. The company was incorporated in 2005 and is headquartered in Chicago, Illinois.
Ownership
Ownership Overview
Top Holders
People Also Watch
FAQ
What Is the Xeris Biopharma (XERS) Stock Price Today?
The Xeris Biopharma stock price today is 9.970 USD.
What Stock Exchange Does Xeris Biopharma Trade On?
Xeris Biopharma is listed and trades on the Nasdaq Stock Exchange.
What Is the Stock Symbol for Xeris Biopharma?
The stock symbol for Xeris Biopharma is "XERS."
What Is the Xeris Biopharma Market Cap?
As of today, Xeris Biopharma market cap is 1.840B USD.
What Is Xeris Biopharma's Earnings Per Share (TTM)?
The Xeris Biopharma EPS (TTM) is -0.10.
When Is the Next Xeris Biopharma Earnings Date?
Xeris Biopharma will release its next earnings report on Nov 05, 2026.
From a Technical Analysis Perspective, Is XERS a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.
How Many Times Has Xeris Biopharma Stock Split?
Xeris Biopharma has split 0 times.
How Many Employees Does Xeris Biopharma Have?
Xeris Biopharma has 435 employees.
What is the current trading status of Xeris Biopharma (XERS)?
As of Oct 15, 2026, Xeris Biopharma (XERS) is trading at a price of 9.970 USD, with a previous close of 9.770 USD. The stock has fluctuated within a day range of 9.770 USD to 10.090 USD, while its 52-week range spans from 5.250 USD to 11.330 USD.
What Is Xeris Biopharma (XERS) Price Target According to Analysts?
The average 12-month price target for Xeris Biopharma is 12.857 USD, with a high estimate of 18 USD and a low estimate of 8 USD. 6 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +28.96% Upside potential.
What Is the XERS Premarket Price?
XERS's last pre-market stock price is 9.850 USD. The pre-market share volume is 102,860.000, and the stock has decreased by 0.080, or 0.820%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.